Stereotaxis Inc  

(Public, NASDAQ:STXS)   Watch this stock  
Find more results for Fred Mills
+0.04 (2.47%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.56 - 1.71
52 week 1.32 - 6.34
Open 1.62
Vol / Avg. 188,325.00/285,207.00
Mkt cap 32.95M
P/E     -
Div/yield     -
EPS -0.58
Shares 20.46M
Beta 3.10
Inst. own 30%
Feb 23, 2015
Q4 2014 Stereotaxis Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 5, 2014
Q3 2014 Stereotaxis Inc Earnings Call - Webcast
Nov 5, 2014
Q3 2014 Stereotaxis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 0.26% -180.79%
Operating margin -13.32% -23.25%
EBITD margin - -20.04%
Return on average assets 0.34% -217.44%
Return on average equity - -
Employees 123 -
CDP Score - -


4320 Forest Park Ave Unit 100
ST. LOUIS, MO 63108-2979
United States - Map
+1-314-6786100 (Phone)
+1-314-6786159 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Stereotaxis, Inc designs, manufactures and markets robotic systems and instruments for use primarily by electrophysiologists for the treatment of abnormal heart rhythms known as cardiac arrhythmias. The Company offers its Epoch Solution, an advanced remote robotic navigation system for use in a hospital�s interventional surgical suite, or interventional lab. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (Niobe ES system), Odyssey Information Management Solution (Odyssey Solution), and the Vdrive Robotic Navigation System (Vdrive system). Its Niobe ES system is the latest generation of the Niobe Robotic Magnetic Navigation System (Niobe system), which allows physicians to more effectively navigate catheters, guidewires and other delivery devices, both its own and those the Company is co-developing through strategic alliances, through the blood vessels and chambers of the heart to treatment sites in order to effect treatment.

Officers and directors

William C. Mills III Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Martin C. Stammer Chief Financial Officer
Age: 32
Bio & Compensation  - Reuters
Karen W. Duros Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
Frank J. Cheng Senior Vice President - Marketing and Business Development
Age: 45
Bio & Compensation  - Reuters
David A. Giffin Vice President - Human Resources
Age: 64
Bio & Compensation  - Reuters
David W. Benfer Independent Director
Age: 66
Bio & Compensation  - Reuters
Joseph D. Keegan Ph.D. Independent Director
Bio & Compensation  - Reuters
Robert J. Messey Independent Director
Age: 69
Bio & Compensation  - Reuters
Fred A. Middleton Independent Director
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Eric N. Prystowsky M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters